COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol.
COVID-19 Infection, Reinfection, and Vaccine Effectiveness in a Prospective Cohort of Arizona Frontline/Essential Workers: The AZ HEROES Research Protocol.
复制标题
DOI：
10.2196/28925
复制
发表时间：
2021-05-26
影响因子：
1.7
通讯作者：
Burgess JL
中科院分区：
文献类型：
--
作者：
Lutrick K;Ellingson KD;Baccam Z;Rivers P;Beitel S;Parker J;Hollister J;Sun X;Gerald JK;Komatsu K;Kim E;LaFleur B;Grant L;Yoo YM;Kumar A;Mayo Lamberte J;Cowling BJ;Cobey S;Thornburg NJ;Meece JK;Kutty P;Nikolich-Zugich J;Thompson MG;Burgess JL
自2019年底以来，COVID-19在全球范围内传播，全球病例数和死亡人数前所未有。卫生保健人员（HCP）、急救人员以及其他基本和一线工作人员（OEWs）由于经常与其他人密切接触，感染SARS-CoV-2的风险增加。亚利桑那州医疗保健、应急响应和其他基本工作者研究（AZ HEROES）旨在研究高职业暴露风险成年人中SARS-CoV-2感染和COVID-19疾病的流行病学。研究目标包括通过症状表现和人口学因素估计医务人员SARS-CoV-2感染发生率，确定职业和社区暴露对SARS-CoV-2感染发生率的独立影响，建立医务人员SARS-CoV-2感染的分子和免疫学特征，描述实时逆转录聚合酶链反应（rRT-PCR）阳性的持续时间和模式。检查疫苗接种后的免疫反应。符合条件的参与者包括年龄在18到85岁之间的亚利桑那州居民，他们每周至少工作20小时，并且经常与他人直接接触（即在3英尺范围内）。招募目标按人口统计学特征（50%的年龄在40岁或以上，50%的女性，50%的西班牙裔或美洲印第安人）、职业（40%的HCP， 30%的第一反应者和30%的OEWs）和先前的SARS-CoV-2感染（基线时高达50%的血清阳性）进行分层。在登记时收集有关社会人口统计学、健康和病史、疫苗接种状况、与疑似或确诊SARS-CoV-2感染者的接触、个人防护装备的使用以及感知风险的信息，并通过季度调查进行更新。参与者每周完成covid -样疾病（CLI）的主动监测，并自行收集鼻拭子。在CLI发作时，收集额外的自采鼻拭子和唾液标本。呼吸道标本被送往马什菲尔德实验室，并通过rRT-PCR检测SARS-CoV-2。CLI症状和对工作和生产力的影响，通过疾病的解决进行跟踪。每3个月采集一次血清标本，并在rRT-PCR阳性事件发生后和每次接种COVID-19疫苗后采集额外的血清。SARS-CoV-2感染发生率将按高危人群周数计算，并按职业和人口统计学特征以及血清阳性状态、感染和疫苗接种史进行比较。AZ HEROES研究是由美国疾病控制和预防中心资助的。2020年7月27日开始招生；截至2021年5月1日，共有3165名参与者参加了该研究。预计入学将持续到2021年12月1日，数据收集将至少持续到2022年4月，具体取决于资金情况。AZ HEROES的独特之处在于旨在招募不同的基本工作人员样本，并前瞻性地跟踪SARS-CoV-2血清阴性和血清阳性的成年人阶层。调查结果将结合暴露、CLI、每周分子诊断检测和定期血清学等主动监测数据，用于估计有症状和无症状SARS-CoV-2感染的发生率，评估对自然感染和COVID-19疫苗接种的免疫反应的强度和持久性，并有助于评估COVID-19疫苗的有效性。derr1 - 10.2196/28925
COVID-19 has spread worldwide since late 2019, with an unprecedented case count and death toll globally. Health care personnel (HCP), first responders, and other essential and frontline workers (OEWs) are at increased risk of SARS-CoV-2 infection because of frequent close contact with others. The Arizona Healthcare, Emergency Response, and Other Essential Workers Study (AZ HEROES) aims to examine the epidemiology of SARS-CoV-2 infection and COVID-19 illness among adults with high occupational exposure risk. Study objectives include estimating the incidence of SARS-CoV-2 infection in essential workers by symptom presentation and demographic factors, determining independent effects of occupational and community exposures on incidence of SARS-CoV-2 infection, establishing molecular and immunologic characteristics of SARS-CoV-2 infection in essential workers, describing the duration and patterns of real-time reverse transcription–polymerase chain reaction (rRT-PCR) positivity, and examining postvaccine immunologic response. Eligible participants include Arizona residents aged 18 to 85 years who work at least 20 hours per week in an occupation involving regular direct contact (ie, within 3 feet) with others. Recruitment goals are stratified by demographic characteristics (50% aged 40 years or older, 50% women, and 50% Hispanic or American Indian), by occupation (40% HCP, 30% first responders, and 30% OEWs), and by prior SARS-CoV-2 infection (with up to 50% seropositive at baseline). Information on sociodemographics, health and medical history, vaccination status, exposures to individuals with suspected or confirmed SARS-CoV-2 infection, use of personal protective equipment, and perceived risks are collected at enrollment and updated through quarterly surveys. Every week, participants complete active surveillance for COVID-like illness (CLI) and self-collect nasal swabs. Additional self-collected nasal swab and saliva specimens are collected in the event of CLI onset. Respiratory specimens are sent to Marshfield Laboratories and tested for SARS-CoV-2 by rRT-PCR assay. CLI symptoms and impact on work and productivity are followed through illness resolution. Serum specimens are collected every 3 months and additional sera are collected following incident rRT-PCR positivity and after each COVID-19 vaccine dose. Incidence of SARS-CoV-2 infections will be calculated by person-weeks at risk and compared by occupation and demographic characteristics as well as by seropositivity status and infection and vaccination history. The AZ HEROES study was funded by the US Centers for Disease Control and Prevention. Enrollment began on July 27, 2020; as of May 1, 2021, a total of 3165 participants have been enrolled in the study. Enrollment is expected to continue through December 1, 2021, with data collection continuing through at least April 2022, contingent upon funding. AZ HEROES is unique in aiming to recruit a diverse sample of essential workers and to prospectively follow strata of SARS-CoV-2 seronegative and seropositive adults. Survey results combined with active surveillance data on exposure, CLI, weekly molecular diagnostic testing, and periodic serology will be used to estimate the incidence of symptomatic and asymptomatic SARS-CoV-2 infection, assess the intensity and durability of immune responses to natural infection and COVID-19 vaccination, and contribute to the evaluation of COVID-19 vaccine effectiveness. DERR1-10.2196/28925
登录
查看更多内容
影响因子：
11.8
作者：
Lynch, John B.;Davitkov, Perica;Sultan, Shahnaz
通讯作者：
Sultan, Shahnaz
影响因子：
82.9
作者：
Long, Quan-Xin;Liu, Bai-Zhong;Huang, Ai-Long
通讯作者：
Huang, Ai-Long
影响因子：
3.7
作者：
Hirsch A;Katz MA;Laufer Peretz A;Greenberg D;Wendlandt R;Shemer Avni Y;Newes-Adeyi G;Gofer I;Leventer-Roberts M;Davidovitch N;Rosenthal A;Gur-Arie R;Hertz T;Glatman-Freedman A;Monto AS;Azziz-Baumgartner E;Ferdinands JM;Martin ET;Malosh RE;Neyra Quijandría JM;Levine M;Campbell W;Balicer R;Thompson MG;SHIRI workgroup
通讯作者：
SHIRI workgroup
影响因子：
3.7
作者：
Baker, Marissa G.;Peckham, Trevor K.;Seixas, Noah S.
通讯作者：
Seixas, Noah S.
DOI：
10.1056/nejmoa2034545
发表时间：
2021-02-11
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lumley SF;O'Donnell D;Stoesser NE;Matthews PC;Howarth A;Hatch SB;Marsden BD;Cox S;James T;Warren F;Peck LJ;Ritter TG;de Toledo Z;Warren L;Axten D;Cornall RJ;Jones EY;Stuart DI;Screaton G;Ebner D;Hoosdally S;Chand M;Crook DW;O'Donnell AM;Conlon CP;Pouwels KB;Walker AS;Peto TEA;Hopkins S;Walker TM;Jeffery K;Eyre DW;Oxford University Hospitals Staff Testing Group
通讯作者：
Oxford University Hospitals Staff Testing Group